Department of Pediatrics, New York Medical College, Valhalla, NY.
Department of Pathology, New York Medical College, Valhalla, NY.
J Natl Compr Canc Netw. 2024 Jun 18;22(5):e247006. doi: 10.6004/jnccn.2024.7006.
Despite excellent cure rates among children, adolescents, and young adults (CAYAs) with mature B-cell non-Hodgkin lymphomas (B-NHLs) treated with chemoimmunotherapy, CAYAs with relapsed/refractory B-NHL remain difficult to treat, with a dismal prognosis. Reinduction and subsequent therapeutic management are not standardized. The armamentarium of active agents against B-NHL, including antibody-drug conjugates, monoclonal antibodies, checkpoint inhibitors, T-cell engagers, CAR T cells, CAR-natural killer (CAR-NK) cells, and cell signaling inhibitors, continues to expand. This article reviews current management practices and novel therapies in this difficult to treat population.
尽管儿童、青少年和青年成人（CAYA）接受化疗免疫治疗后，成熟 B 细胞非霍奇金淋巴瘤（B-NHL）的治愈率非常高，但复发/难治性 B-NHL 的 CAYA 患者仍难以治疗，预后较差。再诱导和随后的治疗管理尚未标准化。针对 B-NHL 的有效药物不断增加，包括抗体药物偶联物、单克隆抗体、检查点抑制剂、T 细胞激活剂、CAR T 细胞、CAR-自然杀伤（CAR-NK）细胞和细胞信号抑制剂。本文综述了这一治疗难度大的人群的当前治疗方法和新疗法。
